Quantification of hepatitis C virus (HCV) RNA is essential for the everyday management of chronic hepatitis C therapy. "Real-time" PCR techniques are potentially more sensitive than classical PCR techniques, are not prone to carryover contamination, and have a consistently wider dynamic range of quantification. Thus, they are rapidly replacing other technologies for routine quantification of HCV RNA. We extensively evaluated the intrinsic characteristics and clinical performance of the m2000 sp -m2000 rt Abbott real-time PCR platform for HCV RNA quantification. The study shows that the m2000 sp -m2000 rt platform is sensitive, specific, and precise; that the results are reproducible; and that the platform has a broad dynamic range of quantification. When comparing HCV RNA levels measured in the same individuals with the m2000 sp -m2000 rt platform and the third-generation branched-DNA assay, a trend toward a modest overestimation of HCV RNA levels was observed in the m2000 sp -m2000 rt platform in all genotypes except genotype 5. The differences, however, were unlikely to have any impact in clinical practice. In conclusion, our study shows that the Abbott m2000 real-time PCR system for HCV RNA quantification is sensitive, specific, and precise; that the results are reproducible; and that the platform's broad dynamic range of quantification is well suited to HCV RNA monitoring in the clinical setting.
Monitoring of hepatitis C virus (HCV) RNA levels is essential for the management of chronic hepatitis C therapy with the combination of pegylated alpha interferon and ribavirin. Indeed, the rapid (undetectable HCV RNA at week 4 of therapy) and early (more than 2 log 10 drop or undetectable HCV RNA at week 12 of therapy) virologic response is a strong predictor of the likelihood of sustained viral eradication and is used to tailor the treatment duration and to improve cure rates (2, 6, 7, 10, 14, 16, 23, 26, 27) . HCV RNA quantification will continue to be of major importance in the management of therapy with the new HCV drugs in development to assess the virologic response and to detect virologic breakthroughs related to viral resistance early enough to alter therapy and rescue antiviral efficacy (20) .
Ideally, HCV RNA quantification assays should be sensitive, specific, accurate, and precise, and the results should be reproducible. They should have a broad range of linear quantification that fully covers the HCV RNA levels observed in clinical practice in both untreated and treated patients, and quantification should be independent of the HCV genotype. Real-time PCR techniques currently are replacing classical PCR methods and the branched-DNA (bDNA) technology, which did not fulfill all of these criteria. Real-time PCR methods are sensitive, with lower limits of detection/quantification on the order of 10 to 15 HCV RNA international units (IU)/ml, and are not prone to carryover contamination. They benefit from a broad dynamic range of quantification of 7 to 8 log 10 units that covers most of the HCV RNA levels encountered in clinical practice.
In this study, we investigated the intrinsic and clinical performances of the recently developed Abbott m2000 real-time PCR system for HCV RNA quantification, which uses the automated extractor m2000 sp and the m2000 rt device for automated real-time PCR amplification and detection of PCR products (m2000 sp -m2000 rt ; Abbott Diagnostic, Chicago, IL).
Assessment of m2000 sp -m2000 rt platform performance. (i) Analytical sensitivity. In order to evaluate the analytical sensitivity of the m2000 sp -m2000 rt assay relative to the manufacturer's stated lower limit of detection (12 IU/ml), serial 1/2 dilutions of the NAP-HCV5E4 standard down to 6.25 IU/ml were tested 20 times.
(ii) Specificity. The specificity of the m2000 sp -m2000 rt assay was assessed by testing the 202 HCV-seronegative clinical specimens from group A.
(iii) Linearity, accuracy, and influence of the HCV genotype. The linearity of quantification in the m2000 sp -m2000 rt platform was assessed by testing the seven samples of the standard panel OptiQuant HCV RNA, which contain up to 5 ϫ 10 6 IU/ml (6.7 log 10 IU/ml). Each panel member dilution was tested six times in the same experiment with the m2000 sp -m2000 rt platform and three times in the same experiment with the third-generation bDNA-based assay, the Versant HCV RNA 3.0 assay. The average measured values were compared with the expected HCV RNA levels. In addition, serial one-fifth dilutions down to signal extinction were tested in 10 genotype 1, 10 genotype 2, 9 genotype 3, 10 genotype 4, 4 genotype 5, and 3 genotype 6 samples from group B. The dilutions were made with the Nucleic Acid Test dilution matrix (AcroMetrix), a defibrinated, delipidized normal human plasma.
We also compared the results of the m2000 sp -m2000 rt platform with those obtained for the same samples with the third-generation bDNA-based assay in the 141 samples from group B. The bDNA assay can be confidently used as a comparator, since it has been shown to be precise and accurate and to equally quantify HCV genotypes 1 to 6, due to the use of a set of 6 capture and 17 extender oligonucleotide probes spanning the full-length 5Ј-noncoding region and the 5Ј third of the core coding region for hybridization of the HCV genome (1, 8, 9, 12, 13, (17) (18) (19) 24) .
Finally, HCV RNA levels obtained with the m2000 sp -m2000 rt platform were compared with those obtained in the same samples with the CAP/CTM assay and the third-generation bDNA-based assay in the 35 HCV-positive samples from group C.
(iv) Precision and reproducibility. In order to assess precision (or intra-assay reproducibility), each member of the OptiQuant HCV RNA panel was tested six times. In order to assess interassay reproducibility, the low positive control and the high positive control provided in the kits were tested 38 times in corresponding runs on different days. HCV RNA quantification. (i) m2000 sp -m2000 rt . HCV RNA was extracted from 500 l of serum in the automated extractor m2000 sp , according to the manufacturer's instructions. The m2000 rt device was then used for automated real-time PCR amplification and detection of PCR products according to the manufacturer's instructions. HCV RNA levels were expressed in IU/ml.
(ii) bDNA. In the Versant HCV RNA 3.0 Assay, HCV RNA was recovered from 50 l of serum and quantified in the semiautomated System 340 bDNA analyzer (Siemens Medical Solutions Diagnostics, Tarrytown, NY), according to the manufacturer's instructions. HCV RNA levels were expressed in IU/ml.
(iii) CAP/CTM. HCV RNA was extracted from 850 l of serum in the automated Cobas AmpliPrep extractor, according to the manufacturer's instructions. The Cobas TaqMan 48 Analyzer was used for automated real-time PCR amplification and detection of PCR products. The generated data were analyzed with Amplilink software. HCV RNA levels were expressed in IU/ml. Statistical analysis. Descriptive statistics are shown as the mean Ϯ standard deviation (SD) or as medians and interquartile ranges as appropriate. Comparisons between groups were made using the Kruskall-Wallis test or the MannWhitney test. The relationship between quantitative variables was studied by means of regression analysis. P values of Ͻ0.05 were considered significant.
RESULTS
Intrinsic performance of the m2000 sp -m2000 rt assay. (i) Analytical sensitivity. Serial 1/2 dilutions of a standard containing 50 IU/ml HCV RNA down to 6.25 IU/ml were tested 20 times in different experiments with the m2000 sp -m2000 rt platform . HCV RNA was detected in 20/20, 20/20, 13/20, and 13/20 replicate tests of samples containing 50 IU/ml (1.7 log 10 IU/ ml), 25 IU/ml (1.4 log 10 IU/ml), 12.5 IU/ml (1.1 log 10 IU/ml), and 6.25 IU/ml (0.8 log 10 IU/ml), respectively. This result was in keeping with the manufacturer's stated lower limit of detection of the assay (12 IU/ml).
(ii) Specificity. The specificity of the m2000 sp -m2000 rt platform was assessed by testing 202 samples from anti-HCVseronegative patients (group A). No sample tested positive above the lower limit of detection of 12 IU/ml (specificity, 100%; 95% confidence interval, 99 to 100%).
(iii) Precision and reproducibility. Precision (intra-assay reproducibility) was assessed by testing the seven members of the OptiQuant HCV RNA standard that contained 0, 1.7, 2.7, 3.7, 4.7, 5.7, and 6.7 log 10 IU/ml, respectively, six times in the same experiment. As shown in Table 1 , the coefficients of variation varied from 0.76% to 7.68%. Interassay variability was assessed by testing both the high positive control and the low positive control, extracted like clinical samples, 38 times in different experiments. The coefficients of variation were 1.98% and 3.91%, respectively (Table 1) .
Accuracy, linear quantification, and influence of the HCV genotype. (i) Linear quantification of standard panel dilutions. The OptiQuant HCV RNA genotype 1b standard panel, containing 5 ϫ 10 1 IU/ml (1.7 log 10 IU/ml) to 5 ϫ 10 6 IU/ml (6.7 log 10 IU/ml), was used to assess the linearity of HCV RNA quantification in the m2000 sp -m2000 rt assay. The panel was tested six times and three times in the same experiments with the m2000 sp -m2000 rt platform and bDNA, respectively. As shown in Fig. 1A , a significant relationship was found between the average measured and the expected HCV RNA levels (r ϭ 0.9980; P Ͻ 0.0001). The difference between the average measured and the expected HCV RNA levels varied from 0.23 to 0.57 log 10 IU/ml. A significant relationship was also found between the average measured and the expected HCV RNA a For intra-assay reproducibility, the seven members of the standard panel (NAP-000 to NAP-HCV5E6) containing 0 to 5 ϫ 10 6 IU/ml, i.e., 6.70 log 10 IU/ml, respectively, were tested six times in the same experiment. For interassay reproducibility, the assay low positive control (LPC) and high positive control (HPC) were tested 38 times in different experiments.
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on January 31, 2020 by guest http://jcm.asm.org/ levels in the bDNA assay (r ϭ 0.9997; P Ͻ 0.0001) (Fig. 1B) . The difference between the average measured and the expected HCV RNA levels varied from 0.21 to 0.33 log 10 IU/ml. The HCV RNA levels of three standards, NAP-000, NAP-HCV5E1, and NAP-HCV5E2, was below the limit of detection of the bDNA assay (615 IU/ml, i.e., 2.79 log 10 IU/ml).
(ii) Quantification of HCV RNA in clinical samples containing HCV genotypes 1 to 6. One hundred and forty-one samples from patients with chronic hepatitis C infected with HCV genotypes 1 to 6 (group B) (see Materials and Methods) were tested with both the m2000 sp -m2000 rt platform and the thirdgeneration bDNA assay. All of these samples fell within the dynamic ranges of quantification of both assays. As shown in Fig. 2 , there was a significant relationship between the HCV RNA levels obtained in the same samples with the m2000 spm2000 rt platform and bDNA for genotypes 1 to 5 (only three genotype 6 samples were tested). The regression lines were slightly above the expected equality line, as a result of higher values obtained with the m2000 sp -m2000 rt platform than with bDNA for the same sample in the majority of cases (131 out of 141 clinical specimens tested) (Fig. 2) . Figure 3A shows a Bland-Altman analysis of the HCV RNA levels measured in the 141 samples from group B by both the m2000 sp -m2000 rt platform and bDNA. The figure plots the difference between the two measured values (the m2000 spm2000 rt platform minus bDNA) as a function of the mean of both measurements. A moderate overestimation of HCV RNA levels by the m2000 sp -m2000 rt platform compared to bDNA was observed in 131 of the 141 samples (92.9%) containing all HCV genotypes (median m2000 sp -m2000 rt minus bDNA difference, 0.30 log 10 IU/ml). Six samples (one genotype 1, two genotype 2, two genotype 4, and one genotype 6) had an m2000 sp -m2000 rt minus bDNA difference below Ϫ1.96 times the mean difference, whereas eight samples (all of genotype 1) had an m2000 sp -m2000 rt minus bDNA difference above ϩ1.96 times the mean difference. The individual differences between the m2000 sp -m2000 rt platform and bDNA, however, were always below 1.0 log 10 IU/ml in these samples. Box plots of individual differences between the two methods are shown for each genotype in Fig. 3B . They confirm the global, very moderate overestimation of HCV RNA levels in the m2000 spm2000 rt platform compared to bDNA independent of the HCV genotype. The median differences were 0.22 log 10 IU/ml for genotype 1, 0.33 log 10 IU/ml for genotype 2, 0.31 log 10 IU/ml for genotype 3, 0.32 log 10 IU/ml for genotype 4, and Ϫ0.08 log 10 IU/ml for genotype 5 (P ϭ 0.013). HCV genotype 6 is not shown in Fig. 3B because only three samples were tested. The expected difference between two successive one-fifth dilutions is 0.70 log 10 IU/ml. The mean Ϯ SD differences between the undiluted sample and the first one-fifth dilution, and between each dilution and the subsequent one, were 0.81 Ϯ 0.12, 0.76 Ϯ 0.12, 0.74 Ϯ 0.08, 0.77 Ϯ 0.13, 0.76 Ϯ 0.11, and 0.75 Ϯ 0.11, respectively (not significantly different).
Comparison with CAP/CTM. Sera from 35 patients with chronic HCV infection with different genotypes (group C) were tested with the m2000 sp -m2000 rt assay, the CAP/CTM assay, and the third-generation bDNA-based assay. Figure 4A shows the better correlation between the m2000 sp -m2000 rt platform and bDNA than between CAP/CTM and bDNA. The greatest differences between CAP/CTM and bDNA were seen for HCV genotype 2 and 4 samples, as reported previously (4) . Figure 4B shows the relationship between HCV RNA levels measured in the same samples by the m2000 sp -m2000 rt platform and CAP/CTM.
DISCUSSION
Our assessment of the intrinsic performance of the m2000 sp -m2000 rt platform for HCV RNA quantification shows the excellent specificity, precision, and reproducibility of the technique, in keeping with previous reports (11, 22) . The manufacturer's stated lower limit of detection of the assay is 12 IU/ml, as confirmed in the present study.
In clinical samples from patients with chronic hepatitis C infected with the six HCV genotypes, we observed a significant relationship between the HCV RNA levels measured in the same samples with the m2000 sp -m2000 rt platform and the third-generation bDNA assay. The use of the third-generation bDNA assay as the comparator was justified by the fact that the assay is accurate and reproducible, quantifies HCV RNA independently of the HCV genotype, and has been well calibrated to the World Health Organization (WHO) international HCV RNA standard, as confirmed in this study ( 1, 8, 9 , 12, 13, 24, 25). The correlation was found for all HCV genotypes (it was not significant for genotype 6, but only three samples could be tested), and the median individual differences between the HCV RNA levels measured in the two assays were below Ϯ0.5 log 10 IU/ml (i.e., a threefold difference) in all but 10 clinical samples.
The HCV RNA quantification panel used in this study was calibrated with the WHO international HCV RNA standard by means of the second-generation bDNA assay (15, 21) . A minor underestimation of HCV RNA levels was observed with both the m2000 sp -m2000 rt platform and the third-generation bDNA assay relative to the expected HCV RNA values, in spite of a linear relationship. When comparing HCV RNA levels measured in the same individuals by both techniques, we observed a trend toward a modest overestimation of HCV RNA levels in the m2000 sp -m2000 rt platform compared to the third-generation bDNA in all genotypes except genotype 5. The differences, however, were unlikely to have any impact on the clinical use of the m2000 sp -m2000 rt platform. Importantly, no sample was substantially underquantified in the m2000 sp -m2000 rt real-time PCR assay relative to bDNA. In contrast, we have shown that another real-time PCR platform for HCV RNA quantification, CAP/CTM, underestimates HCV RNA levels in approximately 30% of HCV genotype 4 and 15% of HCV genotype 2 infections as a probable result of mispairing of the PCR primers and/or TaqMan probe (4). We recently reported two patients infected with HCV genotype 4 with undetectable HCV RNA in CAP/CTM and high viral levels in the m2000 sp -m2000 rt platform and bDNA (5) . When testing the same patients' samples with the m2000 sp -m2000 rt platform, CAP/CTM, and bDNA in the present study, we observed better accuracy of the m2000 sp -m2000 rt platform than CAP/CTM for HCV RNA quantification, especially for HCV genotype 2 and 4 samples. We tested serial dilutions of clinical samples of the different genotypes. Quantification was linear in all cases, whatever the HCV genotype. This is unlike the CAP/CTM assay, in which we found that HCV RNA levels were overestimated in undiluted clinical samples, but not when the same samples were tested after dilution, a phenomenon observed with all six HCV genotypes (4). These findings explain the greater overestimation of HCV RNA levels relative to bDNA in CAP/CTM than with the m2000 sp -m2000 rt platform. The molecular basis for the HCV RNA overestimation by CAP/CTM in undiluted samples is unknown. We hypothesized a biochemical interaction with a blood component during one of the reaction steps, an interaction that vanishes when the concentration of this (B) Distribution of the differences between HCV RNA levels measured in the m2000 sp -m2000 rt platform and bDNA in the same samples according to the HCV genotype (1 to 5). The results are presented as box plots, where the horizontal line represents the median value, the gray boxes the 50th percentiles, and the upper and lower bars the 95th percentiles.
putative component is reduced in diluted samples (4) . The results of the present study suggest that this putative interaction does not occur during the m2000 sp -m2000 rt reaction.
In conclusion, our study shows that the Abbott m2000 realtime PCR system for HCV RNA quantification (the m2000 spm2000 rt platform) is sensitive, specific, and precise; that the results are reproducible; and that its broad dynamic range of quantification is well suited to HCV RNA monitoring in the clinical setting. This is particularly important in the current clinical context. Indeed, novel therapeutic strategies that include HCV protease and polymerase inhibitors will require sensitive and accurate assays with a broad dynamic range of quantification to monitor the virological responses and to tailor treatment in order to prevent resistance. 
